# The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects

> **NCT06148389** · PHASE1 · COMPLETED · sponsor: **Staidson (Beijing) Biopharmaceuticals Co., Ltd** · enrollment: 36 (actual)

## Conditions studied

- Primary Immune Thrombocytopenia

## Interventions

- **DRUG:** STSA-1301 subcutaneous injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06148389
- **Lead sponsor:** Staidson (Beijing) Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-16
- **Primary completion:** 2024-04-03
- **Final completion:** 2024-04-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06148389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06148389, "The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06148389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*